Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors

Von Hippel-Lindau syndrome

Promoting Stress Management and Resilience Among Individuals With Von Hippel- Lindau Disease Propranolol and Von Hippel-Lindau Disease Retrospective Case Series of Trans-scleral Cryotherapy for Retinal Hemangioblastoma Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy 68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors Study of Brain and Spinal Cord Tumor Growth and Cyst Development in Patients With Von Hippel Lindau Disease Assessment of Residual VHL Function in Tumors – Can it Predict the Patients’ Individual Course of Disease? Phase II Study of Vandetanib in Individuals With Kidney Cancer A Phase 2 Study of PT2977 for the Treatment of Von Hippel Lindau Disease-Associated Renal Cell Carcinoma Drivers of Hypoxia-induced Angiogenesis in Tumor Development Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors MyVHL: Patient Natural History Study Metabolic Mapping to Measure Retinal Metabolism Use of Tracking Devices to Locate Abnormalities During Invasive Procedures National Eye Institute Biorepository for Retinal Diseases Study of Sunitinib in Patients With Von Hippel-Lindau (VHL) Disease Contrast-enhanced Ultrasound as a Screening Tool for Kidney Cancer in Patients With Von-Hippel Lindau Genetic Study to Identify Gene Mutations in Participants Previously Enrolled in Clinical Trial NCI-99-C-0053 Who Have Von Hippel-Lindau Syndrome or Are at Risk for Von Hippel-Lindau Syndrome PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors Pazopanib in Von Hippel-Lindau (VHL) Syndrome 17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only) A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab Ranibizumab Injections to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome Screening for Endolymphatic Sac Tumours (ELSTs) in Von Hippel-Lindau (vHL) Patients Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease EYE001 to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome Von Hippel-Lindau Disease Genetic Epidemiology Study Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584 TKI 258 in Von Hippel-Lindau Syndrome (VHL) Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease Natural History and Management of Pancreatic Lesions in Von Hippel-Lindau Disease Sunitinib Malate to Treat Advanced Eye Disease in Patients With Von Hippel-Lindau Syndrome